Evidence map›Paper›PMID 25950141›Full record

ReviewXenotransplantation

Experimental hepatocyte xenotransplantation--a comprehensive review of the literature.

Huidong Zhou, Hong Liu, Mohamed Ezzelarab, Eva Schmelzer, Yi Wang, Jörg Gerlach, Bruno Gridelli, David K C Cooper

Abstract readReview
In one paragraph

Review in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Cell-based liver therapies: past, present and future.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
  6. Article
  7. Article
  8. Article
  9. Cell therapy in chronic liver disease.Current opinion in gastroenterology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huidong ZhouThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Hong LiuThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Mohamed EzzelarabThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Eva SchmelzerMcGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Yi WangCenter for Kidney Transplantation, Second Affiliated Hospital of the University of South China, Hengyang, Hunan, China.
Jörg GerlachMcGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Bruno GridelliMediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, Italy.
David K C CooperThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

Prolonging life-supported pig kidney and heart graft survival in baboons by suppressing inflammationU19AI090959 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOHIUDDIN, MUHAMMAD M · 2010 to 2024
$26.3M
Therapeutic assessment of synthetic heparin sulfates in transplantation modelsP01HL107152 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2011 to 2017
$15.8M
Thromboregulation to Prevent Thrombotic MicroangiopathyU01AI068642 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2005 to 2008
$2.7M
Tolerance to Carbohydrate Antigens in TransplantationR21AI074844 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2007 to 2008
$405k
NHLBI NIH HHS 1P01 HL107152NHLBI NIH HHS P01 HL107152NIAID NIH HHS R21 AI074844NIAID NIH HHS U01 AI068642NIAID NIH HHS U19 AI090959NIAID NIH HHS U19 AI090959-01PHS HHS R21 A1074844
6 · The paper itself

Abstract

Hepatocyte transplantation (Tx) is a potential therapy for certain diseases of the liver, including hepatic failure. However, there is a limited supply of human livers as a source of cells and, after isolation, human hepatocytes can be difficult to expand in culture, limiting the number available for Tx. Hepatocytes from other species, for example, the pig, have therefore emerged as a potential alternative source. We searched the literature through the end of 2014 to assess the current status of experimental research into hepatocyte xenoTx. The literature search identified 51 reports of in vivo cross-species Tx of hepatocytes in a variety of experimental models. Most studies investigated the Tx of human (n = 23) or pig (n = 19) hepatocytes. No studies explored hepatocytes from genetically engineered pigs. The spleen was the most common site of Tx (n = 23), followed by the liver (through the portal vein [n = 6]) and peritoneal cavity (n = 19). In 47 studies (92%), there was evidence of hepatocyte engraftment and function across a species barrier. The data provided by this literature search strengthen the hypothesis that xenoTx of hepatocytes is feasible and potentially successful as a clinical therapy for certain liver diseases, including hepatic failure. By excluding vascular structures, hepatocytes isolated from genetically engineered pig livers may address some of the immunological problems of xenoTx.

Indexed as

AnimalsAnimals, Genetically ModifiedGraft SurvivalHepatocytesHeterograftsHumansModels, AnimalSwineTransplantation, Heterologoushepatocytespigxenotransplantation

Identifiers

PMID25950141
PMCPMC4519403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.